In the general news, a Russian jetliner taking off from the Egyptian Sinai Peninsula was likely downed by a terrorist bomb. In the U.S., October saw 270,000 new jobs, surprising economists, and raising the probability that the Fed will raise rates this year.
In healthcare business news, the average increase in Obamacare exchange premiums was 7.5% this year, pricing many people out of insurance. In M&A, Shire (SHPG) will acquire Dyax (DYAX) for $6.5 Billion, to expand their HAE portfolio. Also, Lexicon (LXRX) struck a deal with Sanofi (SNY) for diabetes drugs development.
In regulatory affairs, the U.S. Senate expanded its investigation into drug price gouging by adding Merck (MRK) and Eli-Lilly (LLY) to the list. Valeant (VRX) and Turing Pharma were the first ones to raise ire. From the FDA, Gilead’s (GILD) HIV cocktail, Genvoya, was approved, as was Nucala, and asthma drug, for GlaxoSmithKline (GSK).